Japan Kidney Cancer Drugs Market Analysis

Japan Kidney Cancer Drugs Market Analysis


$ 3999

Japan kidney cancer drugs market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Rising consumer awareness, technical improvements, and the appeal of kidney and renal cancer drugs goods are all contributing reasons to the market's expansion. Some of the major key players in this market are Pfizer Inc (US), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), etc.

ID: IN10JPPH321 CATEGORY: Pharmaceuticals GEOGRAPHY: Japan AUTHOR: Saloni Shah

Buy Now

Japan Kidney Cancer Drugs Market Analysis Summary

Japan Kidney Cancer Drugs Market is valued at around $340.7 Mn in 2022 and is projected to reach $547.6 Mn by 2030, exhibiting a CAGR of 6.11% during the forecast period 2023-2030.

Patients can manage a wide range of symptoms and side effects linked to kidney illnesses thanks to medications for kidney cancer. Anemia, shortness of breath, and loss of appetite are a few of the symptoms of renal failure that it helps to cure. However, it's thought that the most popular kind of treatment for chronic renal illness is kidney transplantation. When kidney cancer has progressed to the point that it must be removed, surgery to remove the kidney is performed to treat it.

Some of the drugs approved by FDA for the treatment of kidney cancer are:

  1. Afinitor (Everolimus)
  2. Afinitor Disperz (Everolimus)
  3. Aldesleukin
  4. Alymsys (Bevacizumab)
  5. Avastin (Bevacizumab)
  6. Avelumab
  7. Axitinib
  8. Bavencio (Avelumab)
  9. Belzutifan
  10. Bevacizumab
  11. Cabometyx (Cabozantinib-S-Malate)
  12. Cabozantinib-S-Malate
  13. Everolimus
  14. Fotivda (Tivozanib Hydrochloride)
  15. IL-2 (Aldesleukin)
  16. Inlyta (Axitinib)
  17. Interleukin-2 (Aldesleukin)
  18. Ipilimumab

Rising consumer awareness, technical improvements, and the appeal of Kidney & Renal Cancer Drugs goods are all contributing reasons to the market's expansion. The major key players in this market are Pfizer Inc (US), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (US), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Fresenius SE & Co. KGaA (Germany), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US)

Market Dynamics

Market Growth Drivers

The demand for medications to treat kidney cancer is rising as the prevalence of chronic renal disease increases globally. Chronic renal illness affects about 10% of persons, according to the National Kidney Foundation (CKD). More than 90% of kidney cancers are renal cell carcinomas, however microscopic analysis shows that renal pelvis cancer only accounts for 10% of kidney tumours. RCC patients who have clear cell renal cell carcinoma, the most common form, make up roughly 70% of the population. This necessitates a rise in renal cancer medications. As innovative immunotherapies and immune-oncologic medications become more popular, the general use of targeted therapies will be restricted to a subset of patient populations. Programmed death-1 (PD-1) inhibitors are designed to replace TKIs and mTOR inhibitors in first- and second-line RCC conditions. Combination regimens, especially those comprising PD-1 inhibitors, will be introduced in the first-line setting to address important unmet medical requirements, improve progression-free survival, overcome tumour resistance, and maintain quality of life. As a result, this treatment strategy encourages market growth.

Market Restraints

The substantial side effects of these drugs may prevent the kidney cancer market from growing as swiftly as projected. Market expansion may be hampered by side effects such as nausea, fever, and rashes. The high costs connected with these agents limit market expansion. Many individuals cannot afford the generic kidney cancer medicines since they are relatively pricey. As a result, it inhibits market expansion.

Competitive Landscape

Key Players

  • Pfizer Inc (US)
  • AstraZeneca (UK)
  • Bristol-Myers Squibb Company (US)
  • Dr. Reddy's Laboratories Ltd (India)
  • Endo International plc (Ireland)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Sun Pharmaceutical Industries Ltd (India)
  • Mylan N.V. (US)
  • Novartis AG (Switzerland)
  • Lupin (India)
  • Cipla Inc (India)
  • Aurobindo Pharma (India)
  • Fresenius SE & Co. KGaA (Germany)
  • Sanofi (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Abbott (US)

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Japan Kidney Cancer Drugs Market Segmentation

By Type

  • Renal Cell Carcinoma (RCC)
  • Papillary Renal Cell Carcinoma
  • Chromophobe Renal Cell Carcinoma
  • Unclassified Renal Cell Carcinoma
  • Transitional Cell Carcinoma
  • Wilms Tumor (Nephroblastoma)
  • Renal Sarcoma
  • Angiomyolipoma
  • Oncocytoma
  • Others

By Drug Class

  • Monoclonal Antibodies
  • Trastuzumab
  • Pertuzumab
  • mTOR Inhibitors
  • Sirolimus
  • Everolimus
  • Temsirolimus
  • Immune Checkpoint Inhibitor
  • Atezolizumab
  • Avelumab
  • Durvalumab
  • Combined Therapies
  • Interleukin-2
  • Alpha-Interferon
  • Others

By End Users

  • Hospitals
  • Specialty clinics
  • Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Ritu Baliya

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up